about
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer.Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression.Microbiota dysbiosis in select human cancers: Evidence of association and causality.Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: A meta-analysis of prospective epidemiologic studies.Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directionsCorrelation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.Hydrophobic binding peptide-conjugated hybrid lipid-mesoporous silica nanoparticles for effective chemo-photothermal therapy of pancreatic cancer."HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.Microwave ablation of pancreatic tumors.Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data.New Technologies for Analysis of Extracellular Vesicles.Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1.The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective.ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in GLOBACON 2012.Upregulation of the checkpoint protein CHFR is associated with tumor suppression in pancreatic cancers.Editorial: Mendelian Randomization Analysis Identifies Body Mass Index and Fasting Insulin as Potential Causal Risk Factors for Pancreatic Cancer Risk.Microscopic Venous Invasion in Pancreatic Cancer.Pancreatic cancer: Current status and Challenges.Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies.Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy.Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio.Hydroxyeicosatetraenoic acids in patients with pancreatic cancer: a preliminary reportThe Evolution of Carcinogenesis
P2860
Q33624574-C26C07A4-77AB-471C-9A1D-9C76EDB4E1A9Q33750842-EA5A21C2-7B1A-4272-815A-C74266D764BDQ37707088-71BE970A-7DA0-4348-8D66-990350EA434CQ40077721-E4AFEB42-FADA-4DF7-BEBF-3B5CBFF2A3EAQ40079818-D1722203-D6C2-414A-ACA3-66D3530A19DFQ41608480-0C5F0CAC-1F18-477C-9EFD-77A0A43D5C56Q42255560-79C5514C-4A20-44A3-BE3D-B77378F40631Q42378409-BA23E7D7-B3FE-4412-93E5-3CEF4231D68BQ46269586-721224C0-94FC-47BA-A240-92FC872F2E4BQ47107002-47B30FA7-57E7-44C2-8BFA-F24DC4C03B79Q47219061-BEEAA6A4-AF7E-4611-B028-C3469EC883AEQ47578665-1EBF539F-0A1E-4189-A9FC-EC0D11209E0AQ48135155-E806517A-36C0-4679-8652-7FEDC8657192Q48234159-B302397C-12AD-4956-9017-84CF25CF67FBQ49246389-E156EDEF-2B9C-4351-B524-D0A6099BE342Q49284538-F880FC9A-EB13-4E77-BF19-F2BA450AE1F3Q49388105-577A1D37-1F2D-41E8-87F0-419BB758FE73Q49397791-D05DFAFE-BDC2-4231-ADCB-9497E46EB822Q49413106-638A6519-A204-462C-9485-F490C2473256Q49716938-16CB4C5D-9FE6-4D2D-9C23-8F263122F2D2Q50119514-2C615B33-CC64-4516-9427-50563AE68222Q50195669-5DA37B6B-6796-43DC-B893-905043694610Q52372086-267C3BA6-D29B-4A2B-BA6E-01C7BEDA6173Q52579384-84BFB40D-795E-4E0F-8312-F887BD3FFE29Q54959277-45147320-B065-4F18-BF06-B4D9EEB6EDCBQ54965039-EEAC479F-CAAF-446D-B304-CE3365D7C34FQ55104265-BE6AD794-6DCE-4759-8AC6-C63967B81509Q55243901-3802C03C-18F2-462B-A8A8-E50F4AC7DFA3Q55441827-91ADF426-B18E-4168-BD79-7A516D53459FQ57494112-637CDF81-6F14-41E1-8021-8CBEFE39AFB1Q58699503-2C02685E-120D-49F4-992A-6A91AA9B8BF1
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Epidemiology of pancreatic cancer
@ast
Epidemiology of pancreatic cancer
@en
Epidemiology of pancreatic cancer
@nl
type
label
Epidemiology of pancreatic cancer
@ast
Epidemiology of pancreatic cancer
@en
Epidemiology of pancreatic cancer
@nl
prefLabel
Epidemiology of pancreatic cancer
@ast
Epidemiology of pancreatic cancer
@en
Epidemiology of pancreatic cancer
@nl
P2860
P356
P1476
Epidemiology of pancreatic cancer
@en
P2093
Irena Ilic
Milena Ilic
P2860
P304
P356
10.3748/WJG.V22.I44.9694
P407
P5008
P577
2016-11-28T00:00:00Z